Safe and effective pharmacological treatments for severe obesity remain scarce. In this issue, Iepsen et al. show that obese patients with pathogenic melanocortin 4 receptor mutations, the most common form of monogenic obesity, lose weight with glucagon-like peptide 1 (GLP-1) receptor agonist therapy.